Clinical Trial

a Clinical Research of BCMA-Targeted Prime CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma and Plasma Cell Disease

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This is a single arm study to evaluate the efficacy and safety of BCMA-targeted prime CAR-T cells therapy for patients with relapsed/refractory Multiple Myeloma.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2021-02-26; most recent amendment 2025-02-23.
Status change: Active, Not Recruiting → Recruiting 2021-03-01
Trial Details
NCT Number NCT04776330
Lead Sponsor Chongqing Precision Biotech Co., Ltd
Conditions Multiple Myeloma, Neoplasm, Plasma Cell, Multiple Myeloma in Relapse
Enrollment 80 participants
Start Date 2021-03-07
Primary Completion 2026-12-31 (estimated)
Study Completion 2027-07-01 (estimated)
Updated on ClinicalTrials.gov 2025-02-25